Status:
NOT_YET_RECRUITING
Clinical and Treatment Determinant of Prognosis in Glioblastoma
Lead Sponsor:
Assiut University
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Brief Summary
Gliomas represent the most common primary malignant brain tumors in adults, with glioblastoma (WHO grade 4) being the most aggressive subtype. Despite advances in surgical techniques, radiotherapy, an...
Eligibility Criteria
Inclusion
- Adult patients (≥18 years) with histologically confirmed glioma (WHO grades 2-4) Underwent neurosurgical resection (gross total, subtotal, or biopsy only) Received postoperative radiotherapy with or without concurrent and/or adjuvant temozolomide Available pre- and post-operative imaging for EOR assessment Complete medical records and follow-up data
Exclusion
- Recurrent gliomas at presentation Incomplete treatment (e.g., abandonment, death before adjuvant therapy) Lack of imaging or follow-up data
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07197086
Start Date
October 1 2025
End Date
December 1 2026
Last Update
September 29 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.